The Daily Rounds: Longevity & Health Care Brief | April 5, 2026
| | | |

The Daily Rounds: Longevity & Health Care Brief | April 5, 2026

ByThe Healthcare Discovery Team

🧬 Cellular Reprogramming Enters Human Trials — Life Biosciences has launched the first FDA-approved partial de-aging trial, translating Sinclair's epigenetic reprogramming research from animal models to human medicine. 🧠 Gut-Brain Axis Reverses Memory Loss — Stanford's Nature study shows that correcting age-related gut bacteria shifts restores youthful cognitive performance by reactivating vagus nerve signaling to the hippocampus. 🤖 AI Drug Discovery Reaches Clinical Scale — 173+ AI-designed drug candidates are now in clinical trials, and longevity medicine is being advised to prepare for AI therapeutics to arrive in clinical practice imminently. 🦠 Gut Microbiome as Active Immune Regulator — New research reveals gut bacteria actively inject proteins into cells to modulate immunity, and a microbiome-derived molecule doubled lung cancer immunotherapy response rates in mice. 😴 Circadian Fragmentation Doubles Dementia Risk — A large Neurology journal study found that weak or late-peaking daily activity rhythms more than double the risk of dementia, making circadian optimization a key prevention target.

MechanoAge AI platform for breast cancer risk assessment using cellular mechanical age | Healthcare Discovery
|

The Daily Rounds: Longevity & Health Care Brief | April 4, 2026

ByThe Healthcare Discovery Team

🔬 Aging is a coordination failure — The 2026 World Congress on Targeting Longevity is reframing aging as a breakdown between biological systems, shifting strategy from single-target drugs to systems medicine. 🤖 AI drug discovery hits clinical scale — Over 173 AI-discovered drug programs are now in human trials with breakthrough Phase I success rates, and new tools can screen millions of compounds in hours. 🫁 Aging lung cells drive respiratory vulnerability — UCSF researchers pinpointed aging fibroblasts as the trigger for the deadly inflammatory overreaction that makes flu and COVID so dangerous in older adults. 🦠 Gut bacteria directly control immunity — Microbes inject proteins into human cells to manipulate immune responses, a discovery that could lead to an entirely new category of microbiome therapies. 💪 Muscle power predicts survival better than strength — Mayo Clinic Proceedings research shows explosive muscle power has a nearly 7x mortality differential between lowest and highest performers in older women.

Consistent sleep-wake rhythm aligning brain, heart, and metabolic signals for longevity
| | |

Sleep Regularity May Matter More Than Sleep Duration for How Long You Live: What 60,977 People and Three Landmark Studies Reveal About the Dimension of Sleep Most People Ignore

ByThe Healthcare Discovery Team

A landmark UK Biobank study of 60,977 people found that sleep regularity is a stronger predictor of mortality than sleep duration, reducing all-cause death risk by 30 percent. Combined with…

Healthcare Discovery GLP-1 drugs Alzheimer brain EVOKE trial neurodegeneration 2026 showing metabolic signals and brain biomarkers
| | |

GLP-1 Drugs and the Brain: Why the Biggest Alzheimer’s Trial Failed but the Science Is Far From Over

ByThe Healthcare Discovery Team

The EVOKE and EVOKE+ trials of oral semaglutide in 3,808 Alzheimer’s patients failed their primary endpoints, but stunning biomarker data, positive liraglutide brain volume results, and consistent real-world evidence from…

David Fajgenbaum of Every Cure, the nonprofit focused on AI-powered drug repurposing
| | |

The Cure Hiding in Plain Sight: How Every Cure Is Rewriting the Rules of Drug Discovery

ByThe Healthcare Discovery Team

Every Cure is a nonprofit using AI and drug repurposing to uncover treatments hidden inside existing medicines. Founded by physician-scientist David Fajgenbaum after a repurposed drug saved his own life,…